arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Quince Therapeutics, Inc.

QNCX
$31.30 0.00 (0.00%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Bullish
auto_awesome

Analytical Summary

Quince Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $192.0M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 178.4% ↗
FCF / Share $-3.08 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Oct 9, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-75.49M
↓ -370.4% —
FCF / Share Free cash flow per share
$-3.08
↓ -268.3% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health ↓
53
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters